ReviewNitric oxide : biology and chemistry2008
NO-donating NSAIDs and cancer: an overview with a note on whether NO is required for their action.
Review in Nitric oxide : biology and chemistry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 59 citations in OpenAlex.
- Green-Synthesized Silver Nanoparticles UsingAntioxidants (Basel, Switzerland) · 2025Article
- Pros and Cons of Pharmacological Manipulation of cGMP-PDEs in the Prevention and Treatment of Breast Cancer.International journal of molecular sciences · 2021Review
- Inflammation and tumor progression: signaling pathways and targeted intervention.Signal transduction and targeted therapy · 2021Article
- S-Nitrosylation in Tumor Microenvironment.International journal of molecular sciences · 2021Review
- Anti-Inflammatory Drugs as Anticancer Agents.International journal of molecular sciences · 2020Review
- Impact of novel N-aryl piperamide NO donors on NF-κB translocation in neuroinflammation: rational drug-designing synthesis and biological evaluation.Innate immunity · 2018Article
- Nitric Oxide in the Pathogenesis and Treatment of Tuberculosis.Frontiers in microbiology · 2017Review
- Gasotransmitters in cancer: from pathophysiology to experimental therapy.Nature reviews. Drug discovery · 2016Review
- The evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: a cause for optimism.The Journal of pharmacology and experimental therapeutics · 2015Review
- Gene expression profiles of NO- and HNO-donor treated breast cancer cells: insights into tumor response and resistance pathways.Nitric oxide : biology and chemistry · 2014Review
- The role of cyclic nucleotide signaling pathways in cancer: targets for prevention and treatment.Cancers · 2014Article
- The chemopreventive efficacies of nonsteroidal anti-inflammatory drugs: the relationship of short-term biomarkers to long-term skin tumor outcome.Cancer prevention research (Philadelphia, Pa.) · 2013Article
- New NSAID targets and derivatives for colorectal cancer chemoprevention.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2013Review
- Differential inhibition of tumour cell-induced platelet aggregation by the nicotinate aspirin prodrug (ST0702) and aspirin.British journal of pharmacology · 2012Article
- The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine.British journal of pharmacology · 2012Article
- Aspirin and low-dose nitric oxide-donating aspirin increase life span in a Lynch syndrome mouse model.Cancer prevention research (Philadelphia, Pa.) · 2011Article
- NO to breast: when, why and why not?Current pharmaceutical design · 2010Review
- (1S,4S,5S,8R)-8-Nitro-oxy-2,6-dioxa-bicyclo-[3.3.0]octan-4-yl 3,4,5-triacetoxy-benzoate.Acta crystallographica. Section E, Structure reports online · 2009Article
- Signal transduction molecules as targets for cancer prevention.Science signaling · 2009Article
- Anti-Inflammatory Agents for Cancer Therapy.Molecular and cellular pharmacology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Nitric oxide-donating nonsteroidal anti-inflammatory drugs (NO-NSAIDs) consist of a conventional NSAID to which an NO-releasing moiety is attached covalently, often via a spacer molecule. NO-NSAIDs represent an emerging class of compounds with chemopreventive properties against a variety of cancers, demonstrated in preclinical models including cell culture systems and animal tumor models; their potential efficacy in humans has not been assessed. Their mechanism of action appears complex and involves the generation of reactive oxygen species, suppression of microsatellite instability in mismatch repair-deficient cells, and modulation of several signaling cascades that culminate in inhibited cell renewal and enhanced apoptosis. NO, long appreciated to be able to protect from and also promote cancer, is released form NO-NSAIDs and constitutes their defining property. Existing data are consistent with the notion that NO may mediate their anticancer effect. In addition there is evidence that long-term administration of NO-donating compounds is not associated with increased incidence of colon cancer. Whether NO release is required for the anticancer effect of NO-NSAIDs has being questioned by recent data indicating that, at least in the case of NO-aspirin, the NO-releasing moiety may serve as a leaving group while the spacer actually being the moiety responsible for its pharmacological action. Regardless of mechanistic issues, these compounds promise to contribute to the control of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.